Ge Long Hui·2025-10-25 21:07Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration to change the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd, enhancing its product line and market competitiveness [1] Group 1 - The National Medical Products Administration issued a notification approving the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets [1] - Amisulpride Orally Disintegrating Tablets are an improved formulation of Amisulpride Tablets, originally launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - The change in marketing authorization holder to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd will further enrich the company's product offerings [1]